In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
A qualitative descriptive study was conducted to learn about nurses’ experiences administering care to pediatric patients with neuroblastoma who are receiving radioactive therapy.
Researchers randomly assigned patients with RCC to receive 18 mg or 14 mg of lenvatinib plus 5 mg everolimus to determine which produced better HRQOL.
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.